Search research articles
Contact Us
Filters
Showing results (81-90 of 107) with videos related to
Page
of 11
Sort By:
Gynecologic Oncology
|
December 21, 2016
Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial
Gennaro Daniele, Domenica Lorusso, Giovanni Scambia, et al.
The Lancet. Oncology
|
April 18, 2015
Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial
Sandro Pignata, Domenica Lorusso, Giovanni Scambia, et al.
International Journal of Radiation Oncology, Biology, Physics
|
September 10, 2024
Stereotactic Body Radiation Therapy for Oligoprogressive Ovarian Cancer Patients Treated During Poly(ADP-Ribose)-Polymerase Inhibitor Maintenance: Efficacy and Adverse Events From the Epimetheo Retrospective Study
Gabriella Macchia, Donato Pezzulla, Maura Campitelli, et al.
Gynecologic Oncology
|
November 9, 2019
Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome
Sabrina Chiara Cecere, Gaia Giannone, Vanda Salutari, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
May 15, 2021
Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: a retrospective MITO group study
Sabrina Chiara Cecere, Lucia Musacchio, Michele Bartoletti, et al.
Gynecologic Oncology
|
April 29, 2019
Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials
Gennaro Daniele, Laura Arenare, Giovanni Scambia, et al.
British Journal of Cancer
|
July 22, 2022
Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22)
Lucia Musacchio, Daniela Califano, Michele Bartoletti, et al.
International Journal of Radiation Oncology, Biology, Physics
|
April 2, 2025
Treatment of Oligometastatic Parenchymal Lesions in Ovarian Cancer With Stereotactic Ablative Radiation Therapy: A Multicenter Prospective Phase 2 Trial (MITO RT3/RAD)
Gabriella Macchia, Donato Pezzulla, Maura Campitelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 22, 2017
Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study
Sandro Pignata, Giovanni Scambia, Alessandra Bologna, et al.
Gynecologic Oncology
|
June 24, 2023
Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: Results of a Delphi study
Nicoletta Colombo, Angiolo Gadducci, Fabio Landoni, et al.
Page
of 11
Search research articles
Search
Showing results (81-90 of 107) with videos related to
Sort By:
Page
of 11
Gynecologic Oncology
|
December 21, 2016
Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial
Gennaro Daniele, Domenica Lorusso, Giovanni Scambia, et al.
The Lancet. Oncology
|
April 18, 2015
Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial
Sandro Pignata, Domenica Lorusso, Giovanni Scambia, et al.
International Journal of Radiation Oncology, Biology, Physics
|
September 10, 2024
Stereotactic Body Radiation Therapy for Oligoprogressive Ovarian Cancer Patients Treated During Poly(ADP-Ribose)-Polymerase Inhibitor Maintenance: Efficacy and Adverse Events From the Epimetheo Retrospective Study
Gabriella Macchia, Donato Pezzulla, Maura Campitelli, et al.
Gynecologic Oncology
|
November 9, 2019
Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome
Sabrina Chiara Cecere, Gaia Giannone, Vanda Salutari, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
May 15, 2021
Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: a retrospective MITO group study
Sabrina Chiara Cecere, Lucia Musacchio, Michele Bartoletti, et al.
Gynecologic Oncology
|
April 29, 2019
Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials
Gennaro Daniele, Laura Arenare, Giovanni Scambia, et al.
British Journal of Cancer
|
July 22, 2022
Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22)
Lucia Musacchio, Daniela Califano, Michele Bartoletti, et al.
International Journal of Radiation Oncology, Biology, Physics
|
April 2, 2025
Treatment of Oligometastatic Parenchymal Lesions in Ovarian Cancer With Stereotactic Ablative Radiation Therapy: A Multicenter Prospective Phase 2 Trial (MITO RT3/RAD)
Gabriella Macchia, Donato Pezzulla, Maura Campitelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 22, 2017
Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study
Sandro Pignata, Giovanni Scambia, Alessandra Bologna, et al.
Gynecologic Oncology
|
June 24, 2023
Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: Results of a Delphi study
Nicoletta Colombo, Angiolo Gadducci, Fabio Landoni, et al.
Page
of 11